Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma

European Journal of Clinical Investigation

Volumn 42, Issue 12, 2012, Pages 1295-1301

  Wang, Shen Nien ^a,b   Lee, King Teh ^a   Tsai, Chia Jung ^c,d   Chen, Yu Jie ^d   Yeh, Yao Tsung ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d FOOYIN UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Jun N terminal kinase; P38

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CHI SQUARE TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STUDENT T TEST; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84869880809     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12003     Document Type: Article

References (36)

1. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
2. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-69.
3. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
4. Avruch J. MAP kinase pathways: the first twenty years. Biochim Biophys Acta 2007;1773:1150-60.
5. Rincon M, Davis RJ. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 2009;228:212-24.
6. Han J, Lee JD, Tobias PS, Ulevitch RJ. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem 1993;268:25009-14.
7. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13.
8. Hibi M, Lin AN, Smeal T, Minden A, Karin M. Identification of an oncoprotein-responsive and UV-responsive protein-kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-48.
9. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
10. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
11. Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 2003;278:26715-21.
12. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
13. Wang SN, Yeh YT, Yu ML, Wang CL, Lee KT. Serum adiponectin levels in cholesterol and pigment cholelithiasis. Br J Surg 2006;93:981-6.
14. Wang SN, Yeh YT, Yang SF, Chai CY, Lee KT. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol 2006;59:930-4.
15. Engelberg D. Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol 2004;14:271-82.
16. Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011;21:10-20.
17. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007;39:741-9.
18. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008;14:156-65.
19. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY. p38 mitogen-activated protein kinase pathway is involved in protein kinase C alpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 2007;67:4320-7.
20. Spaziani A, Alisi A, Sanna D, Balsano C. Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1. J Biol Chem 2006;281:10983-9.
21. Sakurai T, Maeda S, Chang LF, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 2006;103:10544-51.
22. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C et al. Adiponectin modulates c-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010;139:1762.
23. Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M, Ercolani G et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009;16:413-22.
24. Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007;205:27-36.
25. Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS et al. Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 2009;198:693-701.
26. Ho MC, Huang GT, Tsang YM, Lee PH, Chen DS, Sheu JC et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol 2009;16:848-55.
27. Lu XY, Xi T, Lau WY, Dong H, Xian ZH, Yu H et al. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol 2011;137:567-75.
28. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002;95:1931-7.
29. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005;103:299-306.
30. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY et al. Factors predictive for long-term survival of male patients with hepatocellular carcinoma after curative resection. J Surg Oncol 2007;95:298-303.
31. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 2007;14:2817-23.
32. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007;26:3159-71.
33. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003;22:2034-44.
34. Meriane M, Roux P, Primig M, Fort P, Gauthier-Rouviere C. Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways. Mol Biol Cell 2000;11:2513-28.
35. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, Nishina H et al. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 2008;15:89-93.
36. Bode AM, Dong ZG. The functional contrariety of JNK. Mol Carcinog 2007;46:591-8.